Search Results - "Elizalde, P V"

Correction: Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance by Russo, R. I. Cordo, Béguelin, W., Flaqué, M. C. Díaz, Proietti, C. J., Venturutti, L., Galigniana, N., Tkach, M., Guzmán, P., Roa, J. C., O’Brien, N. A., Charreau, E. H., Schillaci, R., Elizalde, P. V.

Get full text

Correction: Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis by Venturutti, L., Romero, L. V., Urtreger, A. J., Chervo, M. F., Russo, R. I. Cordo, Mercogliano, M. F., Inurrigarro, G., Pereyra, M. G., Proietti, C. J., Izzo, F., Díaz Flaqué, M. C., Sundblad, V., Roa, J. C., Guzmán, P., de Kier Joffé, E. D. Bal, Charreau, E. H., Schillaci, R., Elizalde, P. V.

Get full text

Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 by Venturutti, L., Russo, R. I. Cordo, Rivas, M. A., Mercogliano, M. F., Izzo, F., Oakley, R. H., Pereyra, M. G., De Martino, M., Proietti, C. J., Yankilevich, P., Roa, J. C., Guzmán, P., Cortese, E., Allemand, D. H., Huang, T. H., Charreau, E. H., Cidlowski, J. A., Schillaci, R., Elizalde, P. V.

Get full text

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 by Venturutti, L, Cordo Russo, R I, Rivas, M A, Mercogliano, M F, Izzo, F, Oakley, R H, Pereyra, M G, De Martino, M, Proietti, C J, Yankilevich, P, Roa, J C, Guzmán, P, Cortese, E, Allemand, D H, Huang, T H, Charreau, E H, Cidlowski, J A, Schillaci, R, Elizalde, P V

“…ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in…”
Get full text

Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation by SALATINO, M, BEGUELIN, W, ELIZALDE, P. V, PETERS, M. G, CARNEVALE, R, PROIETTI, C. J, GALIGNIANA, M. D, VEDOY, C. G, SCHILLACI, R, CHARREAU, E. H, SOGAYAR, M. C

“…Progestin regulation of gene expression was assessed in the progestin-dependent murine tumor line C4HD which requires MPA, a synthetic progestin, for in vivo…”
Get full text

Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis by Venturutti, L, Romero, L V, Urtreger, A J, Chervo, M F, Cordo Russo, R I, Mercogliano, M F, Inurrigarro, G, Pereyra, M G, Proietti, C J, Izzo, F, Díaz Flaqué, M C, Sundblad, V, Roa, J C, Guzmán, P, Bal de Kier Joffé, E D, Charreau, E H, Schillaci, R, Elizalde, P V

“…Membrane overexpression of the receptor tyrosine kinase ErbB-2 (MErbB-2) accounts for a clinically aggressive breast cancer (BC) subtype (ErbB-2-positive) with…”
Get full text

Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance by Cordo Russo, R I, Béguelin, W, Díaz Flaqué, M C, Proietti, C J, Venturutti, L, Galigniana, N, Tkach, M, Guzmán, P, Roa, J C, O'Brien, N A, Charreau, E H, Schillaci, R, Elizalde, P V

“…Membrane overexpression of ErbB-2/HER2 receptor tyrosine kinase (membrane ErbB-2 (MErbB-2)) has a critical role in breast cancer (BC). We and others have also…”
Get full text

Interactions between progestins and heregulin (HRG) signaling pathways : HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas by BALANA, M. E, LUPU, R, LABRIOLA, L, CHARREAU, E. H, ELIZALDE, P. V

“…The present study addressed links between progestin and heregulin (HRG) signaling pathways in mammary tumors. An experimental model of hormonal carcinogenesis,…”
Get full text

Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity by SALATINO, Mariana, SCHILLACI, Roxana, PROIETTI, Cecilia J, CARNEVALE, Romina, FRAHM, Isabel, MOLINOLO, Alfredo A, IRIBARREN, Adolfo, CHARREAU, Eduardo H, ELIZALDE, Patricia V

“…The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast…”
Get full text

Involvement of insulin-like growth factors-I and -II and their receptors in medroxyprogesterone acetate-induced growth of mouse mammary adenocarcinomas by Elizalde, Patricia V., Lanari, Claudia, Molinolo, Alfredo A., Guerra, Fabiana K., Balañá, Maria E., Simian, Marina, Iribarren, Adolfo M., Charreau, Eduardo H.

“…The role of the insulin-like growth factors (IGFs) system was investigated in hormone-dependent (HD) and -independent (HI) in vivo lines of the…”
Get full text

Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells by BALANA, Maria Eugenia, LABRIOLA, Leticia, SALATINO, Mariana, MOVSICHOFF, Federico, PETERS, Giselle, CHARREAU, Eduardo H, ELIZALDE, Patricia V

“…The present study focused on interactions between signaling pathways activated by progestins and by type I and II receptor tyrosine kinases (RTKs) in mammary…”
Get full text

Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells by Labriola, Leticia, Salatino, Mariana, Proietti, Cecilia J., Pecci, Adalí, Coso, Omar A., Kornblihtt, Alberto R., Charreau, Eduardo H., Elizalde, Patricia V.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Enhanced expression of angiotensin II receptor subtypes and angiotensin converting enzyme in medroxyprogesterone-induced mouse mammary adenocarcinomas by Guerra, F K, Ciuffo, G M, Elizalde, P V, Charreau, E H, Saavedra, J M

“…Angiotensin II receptors of the AT1 subtype were very highly expressed in medroxyprogesterone-induced ductal adenocarcinomas of the mammary gland in BALB/c…”
Get more information

Heregulin inhibits proliferation via ERKs and phosphatidyl‐inositol 3‐kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells by Puricelli, Lydia, Proiettii, Cecilia J., Labriola, Leticia, Salatino, Mariana, Balañá, María E., Ghiso, Julio Aguirre, Lupu, Ruth, Pignataro, Omar P., Charreau, Eduardo H., Bal de Kier Joffé, Elisa, Elizalde, Patricia V.

“…Heregulin (HRG) and type I receptor tyrosine kinase (RTK) expression was investigated in the highly invasive and metastatic LM3 cell line, our previously…”
Get full text

Differential expression of and responsiveness to transforming growth factor-beta (TGF-beta) isoforms in hormone-dependent and independent lines of mouse mammary tumors by Viegas, M H, Salatino, M, Goin, M, Peters, G, Labriola, L, Costa da cunha, J, Lanari, C, Charreau, E H, Elizalde, P V

“…Transforming growth factor-beta2 (TGF-beta2) and -beta3 mRNA expressions were studied in ductal hormone-dependent (HD) and -independent (HI) in vivo lines of…”
Get more information

Mechanisms of Cell Cycle Arrest in Response to TGF-β in Progestin-Dependent and -Independent Growth of Mammary Tumors by Salatino, Mariana, Labriola, Leticia, Schillaci, Roxana, Charreau, Eduardo H., Elizalde, Patricia V.

“…TGF-β1 modulation of cell cycle components was assessed in an experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced…”
Get full text

Varying patterns of expression of insulin‐like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability by Guerra, Fabiana K., Eijan, Ana Maria, Puricelli, Lydia, Alonso, Daniel F., de Kier Joffé, Elisa Bal, Kornblihtt, Alberto R., Charreau, Eduardo H., Elizalde, Patricia V.

“…We studied the expression of insulin‐like growth factors I (IGF‐I) and II (IGF‐II) and their receptors (IGF‐R) in 2 related murine mammary adenocarcinoma in…”
Get full text

Effects of antiprogestins RU486 and ZK98299 on the expression of cell cycle proteins of a medroxyprogesterone acetate (MPA)-induced murine mammary tumor by Peters, M G, Vanzulli, S, Elizalde, P V, Charreau, E H, Goin, M M

“…This study links the tumor inhibitory effect of anti-progestins RU486 and ZK98299 to the expression of cell cycle proteins. Medroxyprogesterone acetate-induced…”
Get more information

Abstract P6-20-14: Neutralizing soluble tumor necrosis factor alpha overcomes trastuzumab-resistant breast cancer immune evasion by downregulating mucin 4, improving NK cell function and decreasing myeloid-derived suppressor cells in tumor microenvironment by Schillaci, R, Bruni, S, De Martino, M, Mercogliano, MF, Inurrigarro, G, Frahm, I, Proietti, CJ, Elizalde, PV

“…Abstract Background: Novel strategies aimed to overcome trastuzumab (Tz) resistance of HER2+ breast cancer (BC) are needed. Recently, we demonstrated a novel…”
Get full text

Transforming growth factor-β activities in «in vivo» lines of hormone-dependent and independent mammary adenocarcinomas induced by medroxyprogesterone acetate in BALB/c mice by ELIZALDE, P. V, LANARI, C, KORDON, E, TEZON, J, CHARREAU, E. H

“…We have determined the presence of transforming growth factor-beta (TGF-beta)-like polypeptides in mammary adenocarcinomas induced by medroxyprogesterone…”
Get full text